{
    "id": 18288,
    "fullName": "MTOR H2189Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR H2189Y lies within the PI3K/PI4K domain of the Mtor protein (UniProt.org). H2189Y results in increased phosphorylation of Mtor, p70S6K, Akt, and 4EBP1 in culture, and increased mTOR kinase activity compared to wild-type Mtor in an in vitro assay (PMID: 29708815).",
            "references": [
                {
                    "id": 14120,
                    "pubMedId": 29708815,
                    "title": "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29708815"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "H2189Y",
    "createDate": "02/18/2016",
    "updateDate": "02/15/2019",
    "referenceTranscriptCoordinates": {
        "id": 145235,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11124595G>A",
        "cDna": "c.6565C>T",
        "protein": "p.H2189Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16028,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 reduced phosphorylation of p70S6K, AKT, and 4EBP1 in cells with homozygous MTOR H2189, inhibited proliferation of cells with heterozygous or homozygous MTOR H2189Y in culture, and reduced tumor growth in xenograft models (PMID: 29708815).",
            "molecularProfile": {
                "id": 18626,
                "profileName": "MTOR H2189Y"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14120,
                    "pubMedId": 29708815,
                    "title": "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29708815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16027,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 reduced phosphorylation of mTOR, p70S6K, AKT, and 4EBP1, and inhibited proliferation of cells with homozygous MTOR H2189Y in culture, and reduced tumor growth in xenograft models, but did not have a significant effect on cells with heterozygous MTOR H2189Y (PMID: 29708815).",
            "molecularProfile": {
                "id": 18626,
                "profileName": "MTOR H2189Y"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14120,
                    "pubMedId": 29708815,
                    "title": "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29708815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16025,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) inhibited phosphorylation of mTOR, p70S6K, 4EBP1 and proliferation of cells with homozygous MTOR H2189Y, but did not have a significant effect on proliferation of cells with heterozygous MTOR H2189Y, and inhibited tumor growth in xenograft models (PMID: 29708815).",
            "molecularProfile": {
                "id": 18626,
                "profileName": "MTOR H2189Y"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14120,
                    "pubMedId": 29708815,
                    "title": "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29708815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16026,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capivasertib (AZD5363) reduced phosphorylation of mTOR, p70S6K, AKT, and 4EBP1, and inhibited proliferation of cells with homozygous or heterozygous MTOR H2189Y in culture, and reduced tumor growth in xenograft models (PMID: 29708815).",
            "molecularProfile": {
                "id": 18626,
                "profileName": "MTOR H2189Y"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14120,
                    "pubMedId": 29708815,
                    "title": "PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29708815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18626,
            "profileName": "MTOR H2189Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145236,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11124595G>A",
            "cDna": "c.6565C>T",
            "protein": "p.H2189Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145235,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11124595G>A",
            "cDna": "c.6565C>T",
            "protein": "p.H2189Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}